MARKET IS CLOSED
Loading latest tickers...
Market Indices
S&P 500
$7,722.72
+0.73%
NASDAQ 100
$30,807.93
+1.00%
DOW JONES
$51,177.00
+0.49%
NASDAQ Composite
$27,190.86
+1.19%
RUSSELL 2000
$2,815.20
+0.90%
CBOE VIX
$15.31
-6.59%
Sector Heatmap
Technology+1.01%
Financials+0.06%
Healthcare-0.01%
Consumer Cycl+1.13%
Consumer Staples+0.25%
Energy+0.40%
Industrials+0.78%
Materials+0.66%
Real Estate+0.32%
Utilities+0.38%
Comm Services+0.35%
ENLV — Enlivex Ltd. Ordinary Shares
NasdaqEnlivex Ltd. Ordinary Shares
$0.39
-0.04(-8.37%)
- O
- 0.42
- H
- 0.43
- L
- 0.38
- V
- 616.61K
⏱️ End-of-day dataAs of Oct 2, 2026
Chart
About ENLV
Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, it has developed a treasury using the RAIN protocol, which currently serves as the primary treasury reserve asset of the company.
IndustryCommon Stock
SectorNot available
IPO DateJul 31, 2014
Employees34
Stock ExchangeNasdaq
Ticker SymbolENLV
Websitehttps://www.enlivex.com
Key Financial Statistics
| Market Cap | $7.71M |
| P/E Ratio | N/A |
| Dividend Yield | None |
| EPS | N/A |
| Beta | N/A |
| 52-Week Range | $0.38 - $27.15 |
| 52-Week Avg Volume | 175.2K |
| VWAP | $0.40 |
| Transactions | 3,047 |
| Total Recorded Bars | 3,062 days |